Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)

Syndax Pharmaceuticals Inc

Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.
Cash $575.1M; expects profitability; full-year 2026 R&D+SG&A ~$400M excl. $50M stock comp.
Pipeline expanded: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) IND by end 2026; SNDX-62122 (menin inhibitor for MF) IND in 2027.
Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.
Revuforj prescriptions ~1,500 in Q2 (+121% YoY); average treatment duration increasing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.